BACKGROUND
Infectious complications are a major cause of morbidity and non-relapse mortality after CAR-T cell therapy. Respiratory viral infections (RVIs) are frequent, yet their incidence, timing, and immune correlates remain incompletely defined.
METHODS
We retrospectively analyzed laboratory-confirmed RVIs in 563...
S. Einarsdottir, Teng Fei, M. Sotelo-Alva et al.· International Journal of Inf...· 0 citations
It remains uncertain whether lower CD19 expression is clinically relevant for outcomes of CD19 CAR-T therapy of large B-cell lymphoma (LBCL). We conducted an integrative analysis of tumor CD19 levels with centralized quantitative assessment by flow cytometry (FC), immunohistochemistry and RNA-sequencing in a LBCL cohor...
M. Corona, Aaron Gillmor, K. Argyropoulos et al.· Blood Cancer Discovery· 0 citations
The authors propose IL7-Receptor (IL7R/CD127) as an alternative target for T-ALL and propose IL7-Receptor/CD127 CAR-T cells as an alternative target for T-ALL, showing the antitumor efficacy of IL7Rα/CD127 CAR-T cells against T-ALL in preclinical models.
H. Hocine, Undrakh Ganbaatar, Alfredo Amador-Molina et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.